^
Association details:
Biomarker:PAK4 overexpression
Cancer:Solid Tumor
Drug Class:PD1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

PAK4 Inhibition Increases Anti-PD-1 Response in Mouse Models Prompting Phase I Trial

Published date:
12/09/2019
Excerpt:
In tumors with relatively little T cell infiltration or infiltration by antigen-presenting dendritic cells….We found that biopsies of patients who did not respond to PD-1 blockade showed an overexpression of PAK4